Sandoz receives regulatory approval from NMPA for Rosuvastatin

Sandoz has announced that it has received regulatory approval from Chinas National Medical Products Administration (NMPA) for its generic Rosuvastatin, under the NMPAs Quality Consistency Evaluation (QCE) system. Sandoz is the first multinational pharmaceutical company to receive such an approval under the recently introduced QCE system, which aims to ensure that all generic medicines marketed (or manufactured) in China meet internationally recognized quality standards. The QCE regulations are part of a wide-ranging package of healthcare system reforms introduced by the Chinese government over the past few years, which also offer the potential to accelerate national generic registration timelines significantly.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001119 seconds